Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 20/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.69 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.69 |
| ▸ | CDK1 | P06493 | 2/20 | 0.69 |
| ▸ | PIM1 | P11309 | 2/20 | 0.69 |
| ▸ | CDK2 | P24941 | 2/20 | 0.69 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.69 |
| ▸ | CLK2 | P49760 | 2/20 | 0.69 |
| ▸ | GSK3A | P49840 | 2/20 | 0.69 |
| ▸ | GSK3B | P49841 | 2/20 | 0.69 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.69 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.69 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.69 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.69 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.69 |
| ▸ | STK3 | Q13188 | 2/20 | 0.69 |
| ▸ | CAMK2B | Q13554 | 2/20 | 0.69 |
| ▸ | CAMK2G | Q13555 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3987070 | 0.94 | PRKCQ (0.70) | PRKCQCYP3A4CYP2C9CYP2D6MAP4K4 | |
| SCHEMBL13846550 | 0.89 | PRKCQ (0.57) | PRKCQCYP3A4CYP2C9CYP2D6MAP4K4 | |
| SCHEMBL3993191 | 0.85 | PRKCQ (0.72) | PRKCQCYP3A4CYP2C9CYP2D6MAP4K4 | |
| SCHEMBL3986930 | 0.85 | PRKCQ (0.72) | PRKCQCYP3A4CYP2C9CYP2D6MAP4K4 | |
| SCHEMBL13846476 | 0.84 | PRKCQ (0.60) | PRKCQCYP3A4CYP2C9CYP2D6MAP4K4 | |
| SCHEMBL3984172 | 0.82 | PRKCQ (0.60) | PRKCQCYP3A4CYP2C9CYP2D6MAP4K4 | |
| SCHEMBL3986902 | 0.82 | PRKCQ (0.52) | PRKCQCYP3A4CYP2C9CYP2D6MAP4K4 | |
| SCHEMBL1917079 | 0.82 | PRKCQ (1.00) | PRKCQCYP3A4CYP2C9CYP2D6MAP4K4 | |
| SCHEMBL3992715 | 0.82 | PRKCQ (0.67) | PRKCQCYP3A4CYP2C9CYP2D6MAP4K4 | |
| SCHEMBL3987346 | 0.80 | PRKCQ (0.54) | PRKCQCYP3A4CYP2C9CYP2D6MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3046560-B1 | STEM CELL MODULATION II | EPIAXIS THERAPEUTICS PTY LTD (AU) | 2021-01-06 | — | — | EP | disclosed |
| US-20200289437-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | EpiAxis Therapeutics Pty Ltd. (AU) | 2020-09-17 | — | — | US | disclosed |
| US-20200282010-A1 | IMMUNOGENIC COMPOSITIONS AND USES THEREFOR | EPIAXIS THERAPEUTICS PTY LTD (AU) | 2020-09-10 | — | — | US | disclosed |
| CN-111587120-A | Immunogenic compositions and uses thereof | 艾比克斯治疗私人有限公司 | 2020-08-25 | — | — | CN | disclosed |
| US-10736892-B2 | Stem cell modulation II | EpiAxis Therapeutics Pty Ltd. (AU) | 2020-08-11 | — | — | US | disclosed |
| US-20190192509-A1 | Stem Cell Modulation II | EpiAxis Therapeutics Pty Ltd. (AU) | 2019-06-27 | — | — | US | disclosed |
| US-10124001-B2 | Stem cell modulation II | UNIVERSITY OF CANBERRA (AU) | 2018-11-13 | — | — | US | disclosed |
| US-20170266140-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | EpiAxis Therapeutics Pty Ltd. (AU) | 2017-09-21 | — | — | US | disclosed |
| US-20160354367-A1 | Stem Cell Modulation II | UNIVERSITY OF CANBERRA (AU) | 2016-12-08 | — | — | US | disclosed |
| EP-3046560-A1 | STEM CELL MODULATION II | University of Canberra (AU) | 2016-07-27 | — | — | EP | disclosed |
| WO-2015039187-A1 | STEM CELL MODULATION II | UNIVERSITY OF CANBERRA (AU) | 2015-03-26 | — | — | WO | disclosed |
| US-20090291073-A1 | Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same | BAUSCH & LOMB INCORPORATED | 2009-11-26 | — | — | US | disclosed |
| EP-1866286-B1 | PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-05-27 | — | — | EP | disclosed |
| EP-1866286-B1 | PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-05-27 | — | — | EP | disclosed |
| US-7468382-B2 | Pyridine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-23 | — | — | US | disclosed |
| US-7468382-B2 | Pyridine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-23 | — | — | US | disclosed |
| EP-1866286-A1 | PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006105023-A1 | PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-05 | — | — | WO | disclosed |
| US-20060217417-A1 | PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10736892-B2 | Stem cell modulation II | PRKCQ, PRKCI, PRKCG | PRKCQ 1/4885CYP3A4 4784/4885CYP2C9 4469/4885 |
| US-20090291073-A1 | Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same | PRKCQ, PRKCH, PRKCG | PRKCQ 1/4885CYP3A4 4799/4885CYP2C9 4815/4885 |
| US-20170266140-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | PRKCQ, PRKCG, PRKCH | PRKCQ 1/4885CYP3A4 4544/4885CYP2C9 4777/4885 |
| US-20200282010-A1 | IMMUNOGENIC COMPOSITIONS AND USES THEREFOR | NFATC1, PRKCQ, PRKCH | PRKCQ 2/4885CYP3A4 4826/4885CYP2C9 4881/4885 |
| US-20200289437-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | PRKCQ, PRKCG, PRKCH | PRKCQ 1/4885CYP3A4 4544/4885CYP2C9 4777/4885 |
| US-10124001-B2 | Stem cell modulation II | PRKCQ, PRKCI, PRKCG | PRKCQ 1/4885CYP3A4 4784/4885CYP2C9 4469/4885 |
| US-20190192509-A1 | Stem Cell Modulation II | PRKCQ, PRKCI, PRKCG | PRKCQ 1/4885CYP3A4 4784/4885CYP2C9 4469/4885 |
| US-20160354367-A1 | Stem Cell Modulation II | PRKCQ, PRKCI, PRKCG | PRKCQ 1/4885CYP3A4 4784/4885CYP2C9 4469/4885 |
| US-20060217417-A1 | PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | PRKCQ, PRKCH, PRKCZ | PRKCQ 1/4885CYP3A4 1870/4885CYP2C9 2184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.